{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:09:27Z","timestamp":1783987767624,"version":"3.55.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00702"],"award-info":[{"award-number":["PI24\/00702"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00702"],"award-info":[{"award-number":["PI24\/00702"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["FPU21\/06884"],"award-info":[{"award-number":["FPU21\/06884"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-026-00625-1","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:08:26Z","timestamp":1779282506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic vulnerabilities in pleural mesothelioma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-4899","authenticated-orcid":false,"given":"S\u00edlvia","family":"Plans-Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-664X","authenticated-orcid":false,"given":"Cristina","family":"Mu\u00f1oz-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldp047","volume":"93","author":"RM Rudd","year":"2010","unstructured":"Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93:105\u201323. https:\/\/doi.org\/10.1093\/bmb\/ldp047.","journal-title":"Br Med Bull"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41416-021-01462-2","volume":"125","author":"J Obacz","year":"2021","unstructured":"Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, et al. Biological basis for novel mesothelioma therapies. Br J Cancer. 2021;125:1039\u201355. https:\/\/doi.org\/10.1038\/s41416-021-01462-2.","journal-title":"Br J Cancer"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"e001050","DOI":"10.1136\/bmjresp-2021-001050","volume":"9","author":"M Senek","year":"2022","unstructured":"Senek M, Robertson S, Darlison L, Creech L, Tod A. Malignant pleural mesothelioma patients\u2019 experience by gender: findings from a cross-sectional UK-national questionnaire. BMJ Open Respir Res. 2022;9:e001050. https:\/\/doi.org\/10.1136\/bmjresp-2021-001050.","journal-title":"BMJ Open Respir Res"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol J Am Soc Clin Oncol. 2003;21:2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet Lond Engl. 2021;397:375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet Lond Engl"},{"key":"625_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/jcm14031004","volume":"14","author":"G Cardillo","year":"2025","unstructured":"Cardillo G, Waller D, Tenconi S, Di Noia V, Ricciardi S. Malignant pleural mesothelioma: a 2025 update. J Clin Med. 2025;14:1004. https:\/\/doi.org\/10.3390\/jcm14031004.","journal-title":"J Clin Med"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol J Eur Soc Med Oncol. 2022;33:129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1117\/1.JBO.23.10.105003","volume":"23","author":"S Abbas","year":"2018","unstructured":"Abbas S, Simsek Ozek N, Emri S, Koksal D, Severcan M, Severcan F. Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics. J Biomed Opt. 2018;23:1\u201314. https:\/\/doi.org\/10.1117\/1.JBO.23.10.105003.","journal-title":"J Biomed Opt"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s42003-025-07754-0","volume":"8","author":"E Vecchio","year":"2025","unstructured":"Vecchio E, Gallo R, Mimmi S, Gentile D, Giordano C, Straface E, et al. FABP5 is a key player in metabolic modulation and NF-\u03baB dependent inflammation driving pleural mesothelioma. Commun Biol. 2025;8:324. https:\/\/doi.org\/10.1038\/s42003-025-07754-0.","journal-title":"Commun Biol"},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.mrrev.2008.02.002","volume":"659","author":"M Neri","year":"2008","unstructured":"Neri M, Ugolini D, Dianzani I, Gemignani F, Landi S, Cesario A, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res. 2008;659:126\u201336. https:\/\/doi.org\/10.1016\/j.mrrev.2008.02.002.","journal-title":"Mutat Res"},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316. https:\/\/doi.org\/10.1038\/ng.3520.","journal-title":"Nat Genet"},{"key":"625_CR13","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res J Am Assoc Cancer Res. 2003;9:2108\u201313.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.celrep.2019.07.084","volume":"28","author":"R Buj","year":"2019","unstructured":"Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, et al. Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming. Cell Rep. 2019;28:1971\u201380.e8. https:\/\/doi.org\/10.1016\/j.celrep.2019.07.084.","journal-title":"Cell Rep"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-23-0450","volume":"4","author":"NK Tangudu","year":"2024","unstructured":"Tangudu NK, Buj R, Wang H, Wang J, Cole AR, Uboveja A, et al. De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer Res Commun. 2024;4:1174\u201388. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0450.","journal-title":"Cancer Res Commun"},{"key":"625_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86834-7","volume":"11","author":"S Busacca","year":"2021","unstructured":"Busacca S, Zhang Q, Sharkey A, Dawson AG, Moore DA, Waller DA, et al. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Sci Rep. 2021;11:7434. https:\/\/doi.org\/10.1038\/s41598-021-86834-7.","journal-title":"Sci Rep"},{"key":"625_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10637-008-9160-1","volume":"27","author":"HL Kindler","year":"2009","unstructured":"Kindler HL, Burris HA, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest N Drugs. 2009;27:75\u201381. https:\/\/doi.org\/10.1007\/s10637-008-9160-1.","journal-title":"Invest N Drugs"},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4236\/jct.2011.24072","volume":"02","author":"A Ruefli-Brasse","year":"2011","unstructured":"Ruefli-Brasse A, Sakamoto D, Orf J, Rong M, Shi J, Carlson T, et al. Methylthioadenosine (MTA) rescues methylthioadenosine phosphorylase (MTAP)-deficient tumors from purine synthesis inhibition in vivo via non-autonomous adenine supply. J Cancer Ther. 2011;02:523\u201334. https:\/\/doi.org\/10.4236\/jct.2011.24072.","journal-title":"J Cancer Ther"},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1158\/0008-5472.CAN-20-0414","volume":"81","author":"Q Hu","year":"2021","unstructured":"Hu Q, Qin Y, Ji S, Shi X, Dai W, Fan G, et al. MTAP deficiency-induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer. Cancer Res. 2021;81:4964\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0414.","journal-title":"Cancer Res"},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.3390\/ijms26094299","volume":"26","author":"T Kato","year":"2025","unstructured":"Kato T, Tanaka I, Huang H, Okado S, Imamura Y, Nomata Y, et al. Molecular mechanisms of tumor progression and novel therapeutic and diagnostic strategies in mesothelioma. Int J Mol Sci. 2025;26:4299. https:\/\/doi.org\/10.3390\/ijms26094299.","journal-title":"Int J Mol Sci"},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023;13:2412\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0669.","journal-title":"Cancer Discov"},{"key":"625_CR22","unstructured":"Bristol-Myers S. A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 May [cited 2025 May 20]. Report No.: NCT05245500. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05245500"},{"key":"625_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29397-z","volume":"13","author":"O Alhalabi","year":"2022","unstructured":"Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, et al. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022;13:1797. https:\/\/doi.org\/10.1038\/s41467-022-29397-z.","journal-title":"Nat Commun"},{"key":"625_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135. https:\/\/doi.org\/10.1038\/ng.912.","journal-title":"Nat Genet"},{"key":"625_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.celrep.2016.05.096","volume":"16","author":"JM Baughman","year":"2016","unstructured":"Baughman JM, Rose CM, Kolumam G, Webster JD, Wilkerson EM, Merrill AE, et al. NeuCode proteomics reveals Bap1 regulation of metabolism. Cell Rep. 2016;16:583\u201395. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.096.","journal-title":"Cell Rep"},{"key":"625_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1158\/1541-7786.MCR-22-0635","volume":"21","author":"SE Barnett","year":"2023","unstructured":"Barnett SE, Kenyani J, Tripari M, Butt Z, Grosman R, Querques F, et al. BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification. Mol Cancer Res. 2023;21:411\u201327. https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0635.","journal-title":"Mol Cancer Res"},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1073\/pnas.1619588114","volume":"114","author":"F Dai","year":"2017","unstructured":"Dai F, Lee H, Zhang Y, Zhuang L, Yao H, Xi Y, et al. BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response. Proc Natl Acad Sci USA. 2017;114:3192\u20137. https:\/\/doi.org\/10.1073\/pnas.1619588114.","journal-title":"Proc Natl Acad Sci USA"},{"key":"625_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00931-w","volume":"13","author":"C Meiller","year":"2021","unstructured":"Meiller C, Montagne F, Hirsch TZ, Caruso S, de Wolf J, Bayard Q, et al. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med. 2021;13:113. https:\/\/doi.org\/10.1186\/s13073-021-00931-w.","journal-title":"Genome Med"},{"key":"625_CR29","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato T, Sekido Y. NF2\/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19:988. https:\/\/doi.org\/10.3390\/ijms19040988.","journal-title":"Int J Mol Sci"},{"key":"625_CR30","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"MA L\u00f3pez-Lago","year":"2009","unstructured":"L\u00f3pez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009;29:4235\u201349. https:\/\/doi.org\/10.1128\/MCB.01578-08.","journal-title":"Mol Cell Biol"},{"key":"625_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71:873\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2164.","journal-title":"Cancer Res"},{"key":"625_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","volume":"49","author":"SM White","year":"2019","unstructured":"White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, et al. YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. Dev Cell. 2019;49:425\u201343.e9. https:\/\/doi.org\/10.1016\/j.devcel.2019.04.014.","journal-title":"Dev Cell"},{"key":"625_CR33","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, et al. An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis. Cancer Res. 2017;77:5026\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2834.","journal-title":"Cancer Res"},{"key":"625_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00627-5","volume":"8","author":"D Xu","year":"2024","unstructured":"Xu D, Yin S, Shu Y. NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity. NPJ Precis Oncol. 2024;8:133. https:\/\/doi.org\/10.1038\/s41698-024-00627-5.","journal-title":"NPJ Precis Oncol"},{"key":"625_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1101\/gad.317354.118","volume":"32","author":"C Chiasson-MacKenzie","year":"2018","unstructured":"Chiasson-MacKenzie C, Morris ZS, Liu CH, Bradford WB, Koorman T, McClatchey AI. Merlin\/ERM proteins regulate growth factor-induced macropinocytosis and receptor recycling by organizing the plasma membrane: cytoskeleton interface. Genes Dev. 2018;32:1201\u201314. https:\/\/doi.org\/10.1101\/gad.317354.118.","journal-title":"Genes Dev"},{"key":"625_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","volume":"385","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2016.10.020.","journal-title":"Cancer Lett"},{"key":"625_CR37","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol J Eur Soc Med Oncol. 2016;27:2268\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdw427.","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"625_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study. J Clin Oncol J Am Soc Clin Oncol. 2019;37:790\u20138. https:\/\/doi.org\/10.1200\/JCO.2018.79.0543.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"625_CR39","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/s44321-025-00278-4","volume":"17","author":"D Xu","year":"2025","unstructured":"Xu D, Gao Y, Liu S, Yin S, Hu T, Deng H, et al. De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma. EMBO Mol Med. 2025;17:2258\u201398. https:\/\/doi.org\/10.1038\/s44321-025-00278-4.","journal-title":"EMBO Mol Med"},{"key":"625_CR40","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s44321-025-00276-6","volume":"17","author":"J Jia","year":"2025","unstructured":"Jia J, Stathopoulos GT. Pyrimidine addiction: an Achilles\u2019 heel of NF2-altered mesothelioma. EMBO Mol Med. 2025;17:2165\u20137. https:\/\/doi.org\/10.1038\/s44321-025-00276-6.","journal-title":"EMBO Mol Med"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127:1997\u20132005. https:\/\/doi.org\/10.1038\/s41416-022-01979-0.","journal-title":"Br J Cancer"},{"key":"625_CR42","doi-asserted-by":"publisher","first-page":"23780","DOI":"10.18632\/oncotarget.25267","volume":"9","author":"FM Simabuco","year":"2018","unstructured":"Simabuco FM, Morale MG, Pavan ICB, Morelli AP, Silva FR, Tamura RE. p53 and metabolism: from mechanism to therapeutics. Oncotarget. 2018;9:23780\u2013823. https:\/\/doi.org\/10.18632\/oncotarget.25267.","journal-title":"Oncotarget"},{"key":"625_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/B978-0-12-416618-9.00003-0","volume":"542","author":"R Iurlaro","year":"2014","unstructured":"Iurlaro R, Le\u00f3n-Annicchiarico CL, Mu\u00f1oz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 2014;542:59\u201380. https:\/\/doi.org\/10.1016\/B978-0-12-416618-9.00003-0.","journal-title":"Methods Enzymol"},{"key":"625_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41416-019-0661-9","volume":"122","author":"L Urso","year":"2020","unstructured":"Urso L, Cavallari I, Sharova E, Ciccarese F, Pasello G, Ciminale V. Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br J Cancer. 2020;122:52\u201361. https:\/\/doi.org\/10.1038\/s41416-019-0661-9.","journal-title":"Br J Cancer"},{"key":"625_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1916-3","volume":"10","author":"S Sarkar Bhattacharya","year":"2019","unstructured":"Sarkar Bhattacharya S, Thirusangu P, Jin L, Roy D, Jung D, Xiao Y, et al. PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses. Cell Death Dis. 2019;10:1\u201316. https:\/\/doi.org\/10.1038\/s41419-019-1916-3.","journal-title":"Cell Death Dis"},{"key":"625_CR46","doi-asserted-by":"publisher","unstructured":"Lam SK, Yan S, Lam JSM, Feng Y, Khan M, Chen C, et al. Disturbance of the Warburg effect by dichloroacetate and niclosamide suppresses the growth of different sub-types of malignant pleural mesothelioma in vitro and in vivo. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.1020343.","DOI":"10.3389\/fphar.2022.1020343"},{"key":"625_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms24097771","volume":"24","author":"MA Franczak","year":"2023","unstructured":"Franczak MA, Krol O, Harasim G, Jedrzejewska A, Zaffaroni N, Granchi C, et al. Metabolic effects of new glucose transporter (GLUT-1) and lactate dehydrogenase-A (LDH-A) inhibitors against chemoresistant malignant mesothelioma. Int J Mol Sci. 2023;24:9. https:\/\/doi.org\/10.3390\/ijms24097771.","journal-title":"Int J Mol Sci"},{"key":"625_CR48","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41388-022-02283-0","volume":"41","author":"C Lu","year":"2022","unstructured":"Lu C, Yang D, Klement JD, Colson YL, Oberlies NH, Pearce CJ, et al. H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth. Oncogene. 2022;41:2651\u201362. https:\/\/doi.org\/10.1038\/s41388-022-02283-0.","journal-title":"Oncogene"},{"key":"625_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fphar.2017.00373","volume":"8","author":"L Masuelli","year":"2017","unstructured":"Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, et al. In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. Front Pharm. 2017;8:373. https:\/\/doi.org\/10.3389\/fphar.2017.00373.","journal-title":"Front Pharm"},{"key":"625_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/or.2023.8548","volume":"49","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Park KS, Heo SH, Cho MK, Lee SH. Concurrent induction of apoptosis and necroptosis in apigenin\u2011treated malignant mesothelioma cells: reversal of Warburg effect through Akt inhibition and p53 upregulation. Oncol Rep. 2023;49:111. https:\/\/doi.org\/10.3892\/or.2023.8548.","journal-title":"Oncol Rep"},{"key":"625_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326. https:\/\/doi.org\/10.1038\/s41591-022-02103-8.","journal-title":"Nat Med"},{"key":"625_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.534499","volume":"8","author":"M Rossini","year":"2020","unstructured":"Rossini M, Martini F, Torreggiani E, Fortini F, Aquila G, Sega FVD, et al. Metformin induces apoptosis and inhibits Notch1 in malignant pleural mesothelioma cells. Front Cell Dev Biol. 2020;8:534499. https:\/\/doi.org\/10.3389\/fcell.2020.534499.","journal-title":"Front Cell Dev Biol"},{"key":"625_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2016.07.020","volume":"99","author":"H Wu","year":"2016","unstructured":"Wu H, Walker J, Damhuis RA, Brewster DH, Wild SH. Scottish Diabetes Research Network Epidemiology Group. Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. Lung Cancer Amst Neth. 2016;99:194\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.020.","journal-title":"Lung Cancer Amst Neth"},{"key":"625_CR54","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/s0891-5849(02)00800-6","volume":"32","author":"C Riganti","year":"2002","unstructured":"Riganti C, Aldieri E, Bergandi L, Fenoglio I, Costamagna C, Fubini B, et al. Crocidolite asbestos inhibits pentose phosphate oxidative pathway and glucose 6-phosphate dehydrogenase activity in human lung epithelial cells. Free Radic Biol Med. 2002;32:938\u201349. https:\/\/doi.org\/10.1016\/s0891-5849(02)00800-6.","journal-title":"Free Radic Biol Med"},{"key":"625_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25173-7","volume":"12","author":"S Grosso","year":"2021","unstructured":"Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, et al. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun. 2021;12:4920. https:\/\/doi.org\/10.1038\/s41467-021-25173-7.","journal-title":"Nat Commun"},{"key":"625_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"SH Ignatius Ou","year":"2015","unstructured":"Ignatius Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol Publ Int Assoc Study Lung Cancer. 2015;10:387\u201391. https:\/\/doi.org\/10.1097\/JTO.0000000000000360.","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"key":"625_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1067\/mtc.2001.111176","volume":"121","author":"R Bueno","year":"2001","unstructured":"Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;121:225\u201333. https:\/\/doi.org\/10.1067\/mtc.2001.111176.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"625_CR58","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","volume":"7","author":"DC Christoph","year":"2012","unstructured":"Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, et al. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol Publ Int Assoc Study Lung Cancer. 2012;7:1440\u20138. https:\/\/doi.org\/10.1097\/JTO.0b013e318260deaa.","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"key":"625_CR59","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP van Meerbeeck","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol J Am Soc Clin Oncol. 2005;23:6881\u20139. https:\/\/doi.org\/10.1200\/JCO.20005.14.589.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"625_CR60","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22:1438\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00404-6.","journal-title":"Lancet Oncol"},{"key":"625_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69347-x","volume":"14","author":"D Karatkevich","year":"2024","unstructured":"Karatkevich D, Losmanova T, Zens P, Deng H, Dubey C, Zhang T, et al. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment. Sci Rep. 2024;14:18206. https:\/\/doi.org\/10.1038\/s41598-024-69347-x.","journal-title":"Sci Rep"},{"key":"625_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-021-01938-2","volume":"40","author":"Y Gao","year":"2021","unstructured":"Gao Y, Zens P, Su M, Gemperli CA, Yang H, Deng H, et al. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5\u2019-deoxy-5-fluorocytidine (5\u2019-DFCR). J Exp Clin Cancer Res CR. 2021;40:138. https:\/\/doi.org\/10.1186\/s13046-021-01938-2.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"625_CR63","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.lungcan.2003.10.011","volume":"44","author":"GA Otterson","year":"2004","unstructured":"Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL. Cancer and Leukemia Group B. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer Amst Neth. 2004;44:251\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2003.10.011.","journal-title":"Lung Cancer Amst Neth"},{"key":"625_CR64","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41416-020-0912-9","volume":"123","author":"G Li Petri","year":"2020","unstructured":"Li Petri G, El Hassouni B, Sciarrillo R, Funel N, Mantini G, Zeeuw van der Laan EA, et al. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. Br J Cancer. 2020;123:644\u201356. https:\/\/doi.org\/10.1038\/s41416-020-0912-9.","journal-title":"Br J Cancer"},{"key":"625_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet Lond Engl. 2016;387:1405\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(15)01238-6.","journal-title":"Lancet Lond Engl"},{"key":"625_CR66","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15302","volume":"11","author":"D Wang","year":"2023","unstructured":"Wang D, Zhu J, Li N, Lu H, Gao Y, Zhuang L, et al. GC-MS-based untargeted metabolic profiling of malignant mesothelioma plasma. PeerJ. 2023;11:e15302. https:\/\/doi.org\/10.7717\/peerj.15302.","journal-title":"PeerJ"},{"key":"625_CR67","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/mc.23497","volume":"62","author":"G Adhikary","year":"2023","unstructured":"Adhikary G, Shrestha S, Naselsky W, Newland JJ, Chen X, Xu W, et al. Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation. Mol Carcinog. 2023;62:438\u201349. https:\/\/doi.org\/10.1002\/mc.23497.","journal-title":"Mol Carcinog"},{"key":"625_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF00216936","volume":"8","author":"RH Earhart","year":"1990","unstructured":"Earhart RH, Amato DJ, Chang AY, Borden EC, Shiraki M, Dowd ME, et al. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest N Drugs. 1990;8:113\u20139. https:\/\/doi.org\/10.1007\/BF00216936.","journal-title":"Invest N Drugs"},{"key":"625_CR69","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/bjc.2013.66","volume":"108","author":"LE Dalton","year":"2013","unstructured":"Dalton LE, Clarke HJ, Knight J, Lawson MH, Wason J, Lomas DA, et al. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer. 2013;108:1340\u20137. https:\/\/doi.org\/10.1038\/bjc.2013.66.","journal-title":"Br J Cancer"},{"key":"625_CR70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s44276-023-00004-y","volume":"1","author":"LT Gold","year":"2023","unstructured":"Gold LT, Bray SE, Kernohan NM, Henderson N, Nowicki M, Masson GR. The amino-acid stress sensing eIF2\u03b1 kinase GCN2 is a survival biomarker for malignant mesothelioma. BJC Rep. 2023;1:4. https:\/\/doi.org\/10.1038\/s44276-023-00004-y.","journal-title":"BJC Rep"},{"key":"625_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-024-02830-4","volume":"131","author":"J Wei","year":"2024","unstructured":"Wei J, Zhou S, Chen G, Chen T, Wang Y, Zou J, et al. GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression. Br J Cancer. 2024;131:9. https:\/\/doi.org\/10.1038\/s41416-024-02830-4.","journal-title":"Br J Cancer"},{"key":"625_CR72","first-page":"4075","volume":"31","author":"K Kaira","year":"2011","unstructured":"Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, et al. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 2011;31:4075\u201382.","journal-title":"Anticancer Res"},{"key":"625_CR73","doi-asserted-by":"publisher","first-page":"e0150044","DOI":"10.1371\/journal.pone.0150044","volume":"11","author":"D Barbone","year":"2016","unstructured":"Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, et al. Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma. PLoS ONE. 2016;11:e0150044. https:\/\/doi.org\/10.1371\/journal.pone.0150044.","journal-title":"PLoS ONE"},{"key":"625_CR74","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","volume":"12","author":"PW Szlosarek","year":"2006","unstructured":"Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res J Am Assoc Cancer Res. 2006;12:7126\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1101.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"625_CR75","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-22-2642","volume":"29","author":"LC Rogers","year":"2023","unstructured":"Rogers LC, Kremer JC, Brashears CB, Lin Z, Hu Z, Bastos ACS, et al. Discovery and targeting of a noncanonical mechanism of sarcoma resistance to ADI-PEG20 mediated by the microenvironment. Clin Cancer Res J Am Assoc Cancer Res. 2023;29:3189\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2642.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"625_CR76","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s43440-023-00480-6","volume":"75","author":"MM Phillips","year":"2023","unstructured":"Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, et al. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. Pharm Rep PR. 2023;75:570\u201384. https:\/\/doi.org\/10.1007\/s43440-023-00480-6.","journal-title":"Pharm Rep PR"},{"key":"625_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111525","volume":"28","author":"J Carpentier","year":"2025","unstructured":"Carpentier J, Freitas M, Morales V, Bianchi K, Bomalaski J, Szlosarek P, et al. Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma. iScience. 2025;28:111525. https:\/\/doi.org\/10.1016\/j.isci.2024.111525.","journal-title":"iScience"},{"key":"625_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.20517\/cdr.2024.131","volume":"7","author":"M Cioce","year":"2024","unstructured":"Cioce M, Arbitrio M, Poler\u00e0 N, Altomare E, Rizzuto A, De Marco C, et al. Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity. Cancer Drug Resist. 2024;7:45. https:\/\/doi.org\/10.20517\/cdr.2024.131.","journal-title":"Cancer Drug Resist"},{"key":"625_CR79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0014-5793(00)01913-x","volume":"480","author":"BH Rihn","year":"2000","unstructured":"Rihn BH, Mohr S, McDowell SA, Binet S, Loubinoux J, Galateau F, et al. Differential gene expression in mesothelioma. FEBS Lett. 2000;480:95\u2013100. https:\/\/doi.org\/10.1016\/s0014-5793(00)01913-x.","journal-title":"FEBS Lett"},{"key":"625_CR80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s0899-9007(99)00266-x","volume":"16","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutr Burbank Los Angel Cty Calif. 2000;16:202\u20138. https:\/\/doi.org\/10.1016\/s0899-9007(99)00266-x.","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"625_CR81","doi-asserted-by":"publisher","first-page":"18891","DOI":"10.18632\/oncotarget.3783","volume":"6","author":"YY Zaytseva","year":"2015","unstructured":"Zaytseva YY, Harris JW, Mitov MI, Kim JT, Butterfield DA, Lee EY, et al. Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration. Oncotarget. 2015;6:18891\u2013904. https:\/\/doi.org\/10.18632\/oncotarget.3783.","journal-title":"Oncotarget"},{"key":"625_CR82","first-page":"153","volume":"7","author":"EW Gabrielson","year":"2001","unstructured":"Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001;7:153\u20137.","journal-title":"Clin Cancer Res"},{"key":"625_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104910","volume":"214","author":"PV Nuzzo","year":"2025","unstructured":"Nuzzo PV, Rodrigues S, Ribeiro CF, Teixeira IF, Fanelli GN, Bleve S, et al. Targeting cancer metabolism: therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol Hematol. 2025;214:104910. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104910.","journal-title":"Crit Rev Oncol Hematol"},{"key":"625_CR84","doi-asserted-by":"publisher","unstructured":"Karnan S, Ota A, Hasan MN, Murakami H, Rahman ML, Wahiduzzaman M, et al. Targeting fatty acid synthase suppresses tumor development in NF2\/CDKN2A-deficient malignant pleural mesothelioma [Internet]. bioRxiv; 2024 [cited 2025 May 23]. p. 2024.07.14.603191. Available from: https:\/\/doi.org\/10.1101\/2024.07.14.603191.","DOI":"10.1101\/2024.07.14.603191"},{"key":"625_CR85","doi-asserted-by":"publisher","first-page":"e103025","DOI":"10.1371\/journal.pone.0103025","volume":"9","author":"C Robinson","year":"2014","unstructured":"Robinson C, Alfonso H, Woo S, Walsh A, Olsen N, Musk AW, et al. Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. PLoS ONE. 2014;9:e103025. https:\/\/doi.org\/10.1371\/journal.pone.0103025.","journal-title":"PLoS ONE"},{"key":"625_CR86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2013.07.015","volume":"339","author":"G Tuerdi","year":"2013","unstructured":"Tuerdi G, Ichinomiya S, Sato H, Siddig S, Suwa E, Iwata H, et al. Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells. Cancer Lett. 2013;339:116\u201327. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.015.","journal-title":"Cancer Lett"},{"key":"625_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2020.10.031","volume":"144","author":"L Cantini","year":"2021","unstructured":"Cantini L, Pecci F, Hurkmans DP, Belderbos RA, Lanese A, Copparoni C, et al. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. Eur J Cancer. 2021;144:41\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.031.","journal-title":"Eur J Cancer"},{"key":"625_CR88","doi-asserted-by":"publisher","first-page":"11641","DOI":"10.18632\/oncotarget.2604","volume":"5","author":"I Denis","year":"2014","unstructured":"Denis I, Cellerin L, Gregoire M, Blanquart C. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma. Oncotarget. 2014;5:11641\u201352. https:\/\/doi.org\/10.18632\/oncotarget.2604.","journal-title":"Oncotarget"},{"key":"625_CR89","doi-asserted-by":"publisher","first-page":"e0127310","DOI":"10.1371\/journal.pone.0127310","volume":"10","author":"B Cunniff","year":"2015","unstructured":"Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, et al. Disabling mitochondrial peroxide metabolism via combinatorial targeting of peroxiredoxin 3 as an effective therapeutic approach for malignant mesothelioma. PLoS ONE. 2015;10:e0127310. https:\/\/doi.org\/10.1371\/journal.pone.0127310.","journal-title":"PLoS ONE"},{"key":"625_CR90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.freeradbiomed.2017.12.008","volume":"115","author":"B Nuvoli","year":"2018","unstructured":"Nuvoli B, Camera E, Mastrofrancesco A, Briganti S, Galati R. Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane. Free Radic Biol Med. 2018;115:266\u201377. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.12.008.","journal-title":"Free Radic Biol Med"},{"key":"625_CR91","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fphar.2017.00970","volume":"8","author":"DB Oien","year":"2017","unstructured":"Oien DB, Garay T, Eckstein S, Chien J. Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy. Front Pharm. 2017;8:970. https:\/\/doi.org\/10.3389\/fphar.2017.00970.","journal-title":"Front Pharm"},{"key":"625_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108994","volume":"110","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang X, Meng Y, Xu X, Zuo D. The role of glycolysis and lactate in the induction of tumor-associated macrophages immunosuppressive phenotype. Int Immunopharmacol. 2022;110:108994. https:\/\/doi.org\/10.1016\/j.intimp.2022.108994.","journal-title":"Int Immunopharmacol"},{"key":"625_CR93","unstructured":"G\u00f6nl\u00fcg\u00fcr U, Seyfikli Z, Efeo\u011flu T, Y\u0131ld\u0131z E, Nadir A, G\u00f6nl\u00fcg\u00fcr U, et al. Malignant mesothelioma causing transudative pleural effusion. Thorac Res Pract [Internet]. 2021 Oct [cited 2026 Feb 11]. Available from: https:\/\/thoracrespract.org\/articles\/malignant-mesothelioma-causing-transudative-pleural-effusion\/trp1935."},{"key":"625_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers13225664","volume":"13","author":"F Cersosimo","year":"2021","unstructured":"Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, et al. Mesothelioma malignancy and the microenvironment: molecular mechanisms. Cancers. 2021;13:22. https:\/\/doi.org\/10.3390\/cancers13225664.","journal-title":"Cancers"},{"key":"625_CR95","doi-asserted-by":"publisher","first-page":"e1268308","DOI":"10.1080\/2162402X.2016.1268308","volume":"6","author":"S Al-Taei","year":"2016","unstructured":"Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF, Tabi Z. Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer. Oncoimmunology. 2016;6:e1268308. https:\/\/doi.org\/10.1080\/2162402X.2016.1268308.","journal-title":"Oncoimmunology"},{"key":"625_CR96","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-19-2994","volume":"80","author":"P Su","year":"2020","unstructured":"Su P, Wang Q, Bi E, Ma X, Liu L, Yang M, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80:1438\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2994.","journal-title":"Cancer Res"},{"key":"625_CR97","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.4049\/jimmunol.1302801","volume":"192","author":"R Ramakrishnan","year":"2014","unstructured":"Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920\u201331. https:\/\/doi.org\/10.4049\/jimmunol.1302801.","journal-title":"J Immunol"},{"key":"625_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02186-9","volume":"8","author":"F Veglia","year":"2017","unstructured":"Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun. 2017;8:2122. https:\/\/doi.org\/10.1038\/s41467-017-02186-9.","journal-title":"Nat Commun"},{"key":"625_CR99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","volume":"73","author":"LH Tai","year":"2013","unstructured":"Tai LH, de Souza CT, B\u00e9langer S, Ly L, Alkayyal AA, Zhang J, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73:97\u2013107. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1993.","journal-title":"Cancer Res"},{"key":"625_CR100","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","volume":"19","author":"X Michelet","year":"2018","unstructured":"Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018;19:1330\u201340. https:\/\/doi.org\/10.1038\/s41590-018-0251-7.","journal-title":"Nat Immunol"},{"key":"625_CR101","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","volume":"10","author":"PW Szlosarek","year":"2024","unstructured":"Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-meso randomized clinical trial. JAMA Oncol. 2024;10:475\u201383. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6789.","journal-title":"JAMA Oncol"},{"key":"625_CR102","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/bjc.1992.200","volume":"65","author":"OP Solheim","year":"1992","unstructured":"Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 1992;65:956\u201360.","journal-title":"Br J Cancer"},{"key":"625_CR103","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","volume":"86","author":"JM van Haarst","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold CH, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86:342\u20135.","journal-title":"Br J Cancer"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00625-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:46:34Z","timestamp":1783986394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00625-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1038\/s41389-026-00625-1","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ernest Nadal has had research funding from Roche, Pfizer, Merck-Serono, Bristol Myers Squibb. Advisory board and consulting: Amgen, Apollomics, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Genmab, Johnson & Johnson, Lilly, Merck Sharp & Dohme (MSD), Merck-Serono, Pfizer, Pierre Fabre, PharmaMar, Qiagen, Regeneron, Roche, Sanofi and Takeda. Honoraria for lectures: Amgen, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Illumina, Johnson & Johnson, Lilly, Merck Sharp & Dohme (MSD), Merck-Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi and Takeda. Travel support: Roche, Takeda, Johnson and Johnson, and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}